Medical/Pharmaceuticals
Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enr...
2021-03-31 20:00
10159
BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T
VANCOUVER, BC, March 31, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has filed a pre-IND (Investigational New Drug) meeting request ...
2021-03-31 20:00
3513
AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Market
SHANGHAI, March 31, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, and SIFI S.p.A. ("SIFI"), a leading international ophthalmic com...
2021-03-31 19:30
2499
Future Health: Innovative Health Around the World
LONDON, March 31, 2021 /PRNewswire/ -- It started with the UK but the renowned organisers of Future Health Innovation have recently announced the launch of a full series of digital events - the Health Week Series. Concentrating on key markets around the world, there will be a Summer and Autumn ev...
2021-03-31 18:36
2330
CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
SUZHOU, China, March 31, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration ...
2021-03-31 18:20
7280
Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta(TM)
* BLA submission to the U.S. FDA follows successful conclusion of Evive's Global Phase III Clinical Trial for chemotherapy-induced neutropenia in breast cancer patients. * Evive is the first Chinese biologics company to advance a novel biologic product from pre-clinical studies to a complet...
2021-03-31 11:26
2876
Cigna Study Shows Uncertainty about the Future as Leading Cause of Stress
HONG KONG, March 31, 2021 /PRNewswire/ -- Cigna Hong Kong today released the Hong Kong findings of the latest edition of its Cigna COVID-19 Global Impact Study. As part of Cigna's annual 360 Well-Being Survey, this research is the fourth in a series of studies to better understand the impact of t...
2021-03-31 11:09
3862
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
SHANGHAI, March 31, 2021 /PRNewswire/ -- Everest Medicines
2021-03-31 10:27
4321
Menarini Silicon Biosystems launches CELLSEARCH® Circulating Multiple Myeloma Cells Assay, a new non-invasive test to monitor disease status in clinical research studies
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., March 31, 2021 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on mult...
2021-03-31 10:00
5700
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth
SHANGHAI, March 30, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It once again demonst...
2021-03-31 09:11
3843
ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China
* 3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications inGreater China * ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on N...
2021-03-31 09:00
2484
Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma
SAN FRANCISCO and SUZHOU, China, March 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-03-31 08:00
4722
Viva Biotech Announced 2020 Annual Results
The Group's Revenue Surged by 115.7% YoY Revenue from the CFS Business Increased Significantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Internal Growth and External Expansion Financial Highlights of the year ended December 31, 2020: * Reve...
2021-03-31 07:03
4047
binx health Receives FDA CLIA Waiver for Chlamydia and Gonorrhea Test, Expanding Critical Access to Single-Visit Diagnoses
First ever 30-minute, CLIA-waived, molecular PCR Test for CT/NG now available for OBGYN, physician offices and retail settings holding certificates of waiver BOSTON, March 31, 2021 /PRNewswire/ -- binx health, a population health technology company that provides convenient healthcare solutions, a...
2021-03-31 06:11
2307
European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer
mAbxience, a global fully-fledged biotech company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals, is expanding patient access to biological treatments throughoutEurope. MADRID, March 31, 2021 /PRNewswire/ -- On 31 March 2021, the Eur...
2021-03-31 05:30
10826
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing
WETTEREN, Belgium, March 31, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufact...
2021-03-31 01:04
1825
WuXi AppTec Reports Strong 2020 Annual Results
Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 48.1% Year-over-Year toRMB3,565 Mil...
2021-03-30 21:10
4041
Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress
SAN FRANCISCO and SUZHOU, China, March 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-03-30 20:52
4689
Fosun International Announces 2020 Annual Results: Total Revenue Amounted to RMB136.6 Billion, Gathering Strength to Fuel Growth
2020 Annual Results Summary and Recent Highlights: * Total revenue amounted to RMB136.6 billion. Net profit attributable to owners of the parent wasRMB8.02 billion. Industrial operating profit reached RMB8.15 billion. * Global collaboration has been conducted to develop COVID-19 mRNA va...
2021-03-30 20:03
8431
AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline
SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B...
2021-03-30 19:30
2032
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
5854
